Tuesday, November 5, 2024
HomeTagsAP-SA02

AP-SA02

Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a ‘Disarm’ Study of AP-SA02 in Adults With Bacteremia Due to Staphylococcus Aureus

Armata Pharmaceuticals, Inc., a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, announced that the first patient has been...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics